The patent, which expires in 2038, covers the company's method of transdermally administering 250 milligrams to 500 milligrams of CBD daily in the form of a gel or cream.
Zygel is currently being evaluated in CONNECT-FX, a double-blind placebo-controlled study of 204 pediatric Fragile X patients. The study is designed to measure the change in a Fragile X-specific behavioral checklist.
Patients who have completed the double-blind phase are currently enrolling in the 12-month open label phase, and topline data is expected in 2020.
Fragile X syndrome is a rare genetic condition that causes developmental issues such as learning disabilities and cognitive impairment.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel